Regulation of nitric oxide production in health and disease.
Regulation of nitric oxide production in health and disease.
复制标题
DOI：
10.1097/mco.0b013e328332f99d
复制
发表时间：
2010-01
影响因子：
3.1
通讯作者：
Deutz NE
中科院分区：
文献类型：
--
作者：
Luiking YC;Engelen MP;Deutz NE
The purpose of this review is to highlight recent publications examining Nitric Oxide (NO) production in health and disease and its association with clinical nutrition and alterations in metabolism. The role of the cofactor tetrahydrobiopterin (BH4) in NO production and its relation with arginine availability is indicated as an important explanation for the arginine paradox. This offers potential for NO regulation by dietary factors like arginine or its precursors and vitamin C. Because diets with a high saturated fat content induce high plasma fatty acid levels, endothelial NO production is often impaired due to a reduction in NOS3 phosphorylation. Increasing the arginine availability by arginine therapy or arginase inhibition was therefore proposed as a potential therapy to treat hypertension. Recent studies in septic patients and transgenic mice models found that inadequate de novo arginine production from citrulline reduces NO production. Citrulline supplementation may therefore be a novel therapeutic approach in conditions of arginine deficiency. Both lack and excess of NO production in diseases can have various important implications in which dietary factors can play a modulating role. Future research is needed to expand our understanding of the regulation and adequate measurement of NO production at the organ level and by the different NOS isoforms, also in relation to clinical nutrition.
